Knowledge Library
Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies
Chronic neurodegenerative diseases encompass a variety of progressive conditions that affect neurons, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other forms of dementia. They are among the most common and challenging central nervous system (CNS) diseases. “Many companies had stopped their research program into neurodegenerative diseases, but now sophisticated technology advances have became more broadly …Read More >
Evaluation of the efficacy of ADC in vitro and in vivo
Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >
Structure determination: comparison of methods
WuXi AppTec offers comprehensive structural generation solutions for today´s challenging targets. Our experts provide insights and data to support hit finding through to lead optimization.
WuXi Discovery Services Newsletter: November 2021
WuXi Discovery Services Newsletter: June 2021
WuXi Discovery Services Newsletter: April 2021
WuXi Discovery Services Newsletter: March 2021
WuXi Discovery Services Newsletter: February 2021
WuXi Biology GPCR Cell Lines and Assays
G-protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in eukaryotes and play a pivotal role in signaling pathways, making these transmembrane proteins an important drug target class. In recent years, GPCR drug discovery has moved from random ligand screening towards structure-based drug design. WuXi Biology has developed an integrated GPCR …Read More >